<?xml version='1.0' encoding='utf-8'?>
<document id="31865457"><sentence text="Pre- and post-operative counseling for women on hormonal contraceptives receiving sugammadex at an academic hospital."><entity charOffset="82-92" id="DDI-PubMed.31865457.s1.e0" text="sugammadex" /></sentence><sentence text="Sugammadex is a steroid binder and can potentially bind the estrogens and progestins contained within hormonal contraception"><entity charOffset="0-10" id="DDI-PubMed.31865457.s2.e0" text="Sugammadex" /><entity charOffset="16-23" id="DDI-PubMed.31865457.s2.e1" text="steroid" /><entity charOffset="60-69" id="DDI-PubMed.31865457.s2.e2" text="estrogens" /><pair ddi="false" e1="DDI-PubMed.31865457.s2.e0" e2="DDI-PubMed.31865457.s2.e0" /><pair ddi="false" e1="DDI-PubMed.31865457.s2.e0" e2="DDI-PubMed.31865457.s2.e1" /><pair ddi="false" e1="DDI-PubMed.31865457.s2.e0" e2="DDI-PubMed.31865457.s2.e2" /><pair ddi="false" e1="DDI-PubMed.31865457.s2.e1" e2="DDI-PubMed.31865457.s2.e1" /><pair ddi="false" e1="DDI-PubMed.31865457.s2.e1" e2="DDI-PubMed.31865457.s2.e2" /></sentence><sentence text=" Therefore, the FDA label for sugammadex contains a drug-drug interaction warning between this medication and hormonal contraception, advising that women taking hormonal contraception use a backup contraceptive method or abstinence for seven days after exposure to sugammadex"><entity charOffset="30-40" id="DDI-PubMed.31865457.s3.e0" text="sugammadex" /><entity charOffset="265-275" id="DDI-PubMed.31865457.s3.e1" text="sugammadex" /><pair ddi="false" e1="DDI-PubMed.31865457.s3.e0" e2="DDI-PubMed.31865457.s3.e0" /><pair ddi="false" e1="DDI-PubMed.31865457.s3.e0" e2="DDI-PubMed.31865457.s3.e1" /></sentence><sentence text=" However, given concerns that this warning may not be appropriately provided to at-risk patients, we conducted a retrospective chart review to identify women administered sugammadex while using hormonal contraception to identify documented counseling on this drug-drug interaction prior to implementation of a formalized counseling process" /><sentence text=" We reviewed 1000 randomly selected charts from the University of Colorado Hospital between January 2016 and December 2017" /><sentence text=" We identified 134 women using hormonal contraception at the time of sugammadex exposure; only one patient (0"><entity charOffset="69-79" id="DDI-PubMed.31865457.s6.e0" text="sugammadex" /></sentence><sentence text="7%, 95% CI 0" /><sentence text="0, 4" /><sentence text="1) had documented counseling" /><sentence text=" One patient had an unintended pregnancy within the same cycle as her exposure to sugammadex"><entity charOffset="82-92" id="DDI-PubMed.31865457.s10.e0" text="sugammadex" /></sentence><sentence text=" Improved counseling processes are needed to avoid unnecessary risk for unintended pregnancies" /><sentence text="" /></document>